A Study on the Efficacy, Safety, and Tolerability of Perhexiline Maleate in Subjects With Hypertrophic Cardiomyopathy and Moderate-To-Severe Heart Failure
Status: Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 17 Jul 2017
Price : $35 *
At a glance
- Drugs Perhexiline (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Registrational; Therapeutic Use
- Sponsors HMBL Limited
- 12 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jul 2017.
- 12 Jul 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Apr 2015 Status changed from planning to not yet recruiting, as reported by ClinicalTrials.gov.